Skip to main content
TipRanks
Go Ultimate75% OFF

Bafna Pharmaceuticals Limited (BAFNAPH) AI Stock Analysis

0 Followers
IN:BAFNAPH

Bafna Pharmaceuticals Limited

(NSE:BAFNAPH)

Select Model
Rating:46Neutral
Price Target:INR 467.00â–¼(-2.10% Downside)
Action:reiterated
Date:10/08/26

The overall score is heavily pressured by extremely poor technical and valuation metrics. The stock is deeply overbought with an RSI of 86.9 and carries an unsustainably high P/E ratio of 119.76, both scoring at the minimum. These factors overshadow the company's solid balance sheet and moderate financial performance, which is itself strained by declining margins and negative free cash flow. The primary risk is a potential sharp correction from overbought levels on an already overvalued stock.

Positive Factors
Strong revenue growthThe multi-year expansion in revenue indicates that the company has increased its commercial scale across its pharmaceutical operations. Sustained top-line growth can support broader market reach, improve operating leverage, and provide a foundation for continued investment in products, manufacturing, and distribution.
Negative Factors
Persistently weak free cash flowNegative free cash flow in most of the period shows that reported profitability has not consistently converted into cash available for debt reduction, reinvestment, or shareholder returns. If this pattern persists, financial flexibility may remain constrained and reliance on external funding could increase.

Bafna Pharmaceuticals Limited (BAFNAPH) vs. iShares MSCI India ETF (INDA)

-50%0%50%100%150%200%IN:BAFNAPH+184.86%INDA-5.96%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 11.36B
Dividend Yield
―
Average Volume (3M)
6,324
Price to Earnings (P/E)
96.8
Beta (1Y)
0.58
Revenue Growth
8.74%
EPS Growth
31.20%
Country
India
Employees
339
Sector
General
Sector Strength
55
Industry
Medical - Pharmaceuticals

Bafna Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries....

Bafna Pharmaceuticals Limited Financial Statement Overview

Summary

Financial performance is mixed. The balance sheet is strong (Score 78) with low leverage and growing equity. However, the income statement (Score 48) shows significant margin compression, and the cash flow statement (Score 42) reveals persistent negative free cash flow due to heavy capex. The overall profile is weighed down by profitability and cash burn concerns despite a solid foundation.

Income Statement

48Neutral

Balance Sheet

78Positive

Cash Flow

42Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.44B1.51B1.46B1.52B1.15B851.40M
Gross Profit329.05M201.42M168.77M452.15M175.56M137.18M
EBITDA166.13M207.04M117.73M146.34M189.88M112.34M
Net Income77.86M111.00M41.52M73.48M113.38M52.16M
Balance Sheet
Total Assets01.76B1.53B1.48B1.30B901.45M
Cash, Cash Equivalents and Short-Term Investments20.25M20.25M34.33M13.96M78.09M194.00K
Total Debt0374.33M281.99M243.89M229.24M110.59M
Total Liabilities-961.50M793.83M682.73M668.43M561.29M281.81M
Stockholders Equity961.50M961.50M848.07M808.39M734.55M619.64M
Cash Flow
Free Cash Flow-71.04M-130.76M-23.31M-60.93M-32.66M21.87M
Operating Cash Flow93.13M118.27M195.29M94.85M49.52M97.28M
Investing Cash Flow-149.13M-224.69M-213.02M-150.54M-74.93M-65.44M
Financing Cash Flow24.23M92.35M38.09M-8.45M101.77M-48.15M

Bafna Pharmaceuticals Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price477.00

Price Trends

50DMA402.28Positive
100DMA325.67Positive
200DMA228.10Positive

Market Momentum

MACD21.04Positive
RSI65.45Neutral
STOCH68.20Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAFNAPH, the sentiment is Positive. The current price of 477.00 is above the 20-day moving average (MA) of 461.90, above the 50-day MA of 402.28, and above the 200-day MA of 228.10, indicating a bullish trend. The MACD of 21.04 indicates Positive momentum. The RSI at 65.45 is Neutral, neither overbought nor oversold. The STOCH value of 68.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BAFNAPH.

Bafna Pharmaceuticals Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:BAFNAPH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:SUPRIYAIN:SUPRIYA66NeutralINR 49.48B27.93―0.16%23.00%-2.84%
IN:KILITCHIN:KILITCH65NeutralINR 8.07B32.97――13.87%-17.80%
IN:SANOFIIN:SANOFI65NeutralINR 74.32B20.42―3.81%-5.74%2.30%
IN:HIKALIN:HIKAL57NeutralINR 27.54B-557.88―0.27%8.93%-149.51%
IN:WOCKPHARMAIN:WOCKPHARMA57NeutralINR 329.37B80.36――25.70%―
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:BAFNAPHIN:BAFNAPH46NeutralINR 11.36B96.79――8.74%31.20%

* General Sector Average

Performance Comparison

0%50%100%150%IN:BAFNAPHIN:HIKALIN:KILITCHIN:SANOFIIN:SUPRIYAIN:WOCKPHARMADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:BAFNAPH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:BAFNAPHBafna Pharmaceuticals Limited477.00306.15179.19%
IN:HIKALHikal Limited223.35-4.55-2.00%
IN:KILITCHKilitch Drugs (India) Limited230.9049.7527.46%
IN:SANOFISanofi India Limited3231.65-1177.66-26.71%
IN:SUPRIYASupriya Lifescience Limited614.85-156.38-20.28%
IN:WOCKPHARMAWockhardt Limited2027.10702.2053.00%

Bafna Pharmaceuticals Limited Corporate Events

Bafna Pharmaceuticals Approves Unaudited Results for Quarter and Half Year Ended September 2026

Nov 11, 2026

Bafna Pharmaceuticals Limited manufactures pharmaceutical formulations, which the company identifies as its only operating segment under Ind AS 108. Its board on November 11, 2026 approved unaudited financial results for the quarter and half year end...

Bafna Pharmaceuticals Shuts Trading Window Ahead of Q2 FY27 Results

Sep 26, 2026

Bafna Pharmaceuticals Limited has announced the closure of its trading window for designated persons and their immediate relatives, in line with the SEBI (Prohibition of Insider Trading) Regulations and its own insider trading code. The window will b...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 07, 2026